US Food and Drug Administration Approves First Vaccine to Complete the Rotavirus Immunization Series by 4 Months

被引：0
|
作者：
Nahlen, Dawn Drennan
机构：
来源：
NEWBORN AND INFANT NURSING REVIEWS | 2008年 / 8卷 / 03期
关键词：
D O I：
暂无
中图分类号：
R47 [护理学];
学科分类号：
1011 ;
摘要：
引用
收藏
页码：E33 / E33
页数：1
相关论文
共 50 条
  • [31] Time from US Food and Drug Administration approval to publication of data for cancer drugs: a comparison of first and subsequent approvals
    Lammers, Austin
    Wang, Ruibin
    Cetnar, Jeremy
    Prasad, Vinay
    BLOOD CANCER JOURNAL, 2017, 7
  • [32] COVID-19 Vaccine Uptake and Intentions Following US Food and Drug Administration Approval of the Pfizer-BioNTech COVID-19 Vaccine COMMENT & RESPONSE
    Cohen, Kenneth R.
    JAMA INTERNAL MEDICINE, 2022, 182 (06) : 687 - 688
  • [33] How a patient advocacy group developed the first proposed draft guidance document for industry for submission to the US Food and Drug Administration
    Furlong, Pat
    Bridges, John F. P.
    Charnas, Lawrence
    Fallon, Justin R.
    Fischer, Ryan
    Flanigan, Kevin M.
    Franson, Timothy R.
    Gulati, Neera
    McDonald, Craig
    Peay, Holly
    Sweeney, H. Lee
    ORPHANET JOURNAL OF RARE DISEASES, 2015, 10
  • [34] Time to treatment discontinuation as a pragmatic endpoint: A US Food and Drug Administration pooled analysis of CDK 4/6 inhibitors
    Gao, J. J.
    Gong, Y.
    Cheng, J.
    Schroeder, R. J.
    Amiri-Kordestani, L.
    Khozin, S.
    Kluetz, P.
    Sridhara, R.
    Pazdur, R.
    Blumenthal, G.
    Beaver, J. A.
    Prowell, T. M.
    CANCER RESEARCH, 2019, 79 (04)
  • [35] Leflunomide use during the first 33 months after food and drug administration approval: Experience with a national cohort of 3,325 patients
    Siva, C
    Eisen, SA
    Shepherd, R
    Cunningham, F
    Fang, MA
    Finch, W
    Salisbury, D
    Singh, JA
    Stern, R
    Zarabadi, SA
    ARTHRITIS & RHEUMATISM-ARTHRITIS CARE & RESEARCH, 2003, 49 (06): : 745 - 751
  • [36] Benefit of CDK 4/6 inhibition in less common breast cancer subsets: A US Food and Drug Administration pooled analysis
    Gao, Jennifer J.
    Cheng, Joyce
    Bloomquist, Erik
    Schroeder, Robert
    Amiri-Kordestani, Laleh
    Sridhara, Rajeshwari
    Blumenthal, Gideon Michael
    Pazdur, Richard
    Beaver, Julia A.
    Prowell, Tatiana Michelle
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
  • [37] Bavarian Nordic Announces US Food and Drug Administration Approval of JYNNEOS (Smallpox and Monkeypox Vaccine, Live, Nonreplicating) for Prevention of Smallpox and Monkeypox Disease in Adults
    Kaye, Donald
    CLINICAL INFECTIOUS DISEASES, 2020, 70 (02) : I - I
  • [38] The First 4 Years of Postmarketing Safety Surveillance Related to the MitraClip Device: A United States Food and Drug Administration MAUDE Experience
    Mahabir, Chetaj A.
    DeFilippis, Ersilia M.
    Aggarwal, Sourabh
    Bath, Anandbir
    Qamar, Arman
    Patel, Nilay K.
    Goldsweig, Andrew M.
    Vaduganathan, Muthiah
    JOURNAL OF INVASIVE CARDIOLOGY, 2020, 32 (05): : E130 - E132
  • [39] Dipeptidyl Peptidase 4 Inhibitors and Gallbladder or Biliary Diseases: Data From the US Food and Drug Administration Adverse Event Reporting System
    He, Liyun
    Wang, Jialu
    Li, Ziyi
    Li, Yuxiu
    Zhang, Huabing
    DIABETES CARE, 2023, 46 (02) : E72 - E73
  • [40] Contemporary Trends in Prescription of Dipeptidyl Peptidase-4 Inhibitors in the Context of US Food and Drug Administration Warnings of Heart Failure Risk
    Vaduganathan, Muthiah
    Singh, Avinainder
    Sharma, Abhinav
    Januzzi, James L.
    Scirica, Benjamin M.
    Butler, Javed
    Zannad, Faiez
    McGuire, Darren K.
    Cannon, Christopher P.
    Bhatt, Deepak L.
    AMERICAN JOURNAL OF CARDIOLOGY, 2020, 125 (10): : 1577 - 1581
12345